Pharmacologic treatment of fibromyalgia

被引：8

作者：

Barkhuizen A. ^{[1
]}

机构：

[1] Department of Medicine (L329A), Oregon Health Sciences University and Portland VA Medical Center, 3181 SW Sam Jackson Park Road, Portland, 97201, OR

来源：

Current Pain and Headache Reports | 2001年 / 5卷 / 4期

关键词：

Fibromyalgia; Interstitial Cystitis; Irritable Bowel Syndrome; Myofascial Pain; Tramadol;

D O I：

10.1007/s11916-001-0025-y

中图分类号：

学科分类号：

摘要：

Fibromyalgia is a chronic syndrome characterized by widespread pain, unrefreshed sleep, disturbed mood, and fatigue. Until such time as we have a clearer understanding of the trigger and/or pathophysiologic mechanisms producing these symptoms, pharmacologic treatment should be aimed at individual symptoms. Such treatment should ideally be offered as part of a multidisciplinary treatment program using both pharmacologic and nonpharmacologic treatment modalities. Critical components of any successful fibromyalgia treatment program include addressing physical fitness, work and other functional activities, and mental health, in addition to symptom-specific therapies. The main symptoms that should be addressed include pain, sleep disturbances including restless leg syndrome, mood disturbances, and fatigue. Pharmacologic therapy should also be considered for syndromes commonly associated with fibromyalgia including irritable bowel syndrome, interstitial cystitis, migraine headaches, temporomandibular joint dysfunction, dysequilibrium including neurally mediated hypotension, sicca syndrome, and growth hormone deficiency. This article provides general guidelines in initiating a successful pharmacologic treatment program for fibromyalgia. © 2001, Current Science Inc.

引用

页码：351 / 358

页数：7

共 73 条

[21]

Wolfe F., Anderson J., Harkness D., Et al., A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia, Arthritis Rheum, 40, pp. 1560-1570, (1997)

[22]

Wolfe F., Zhao S., Lane N., Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients, Arthritis Rheum, 43, pp. 378-385, (2000)

[23]

Leventhal L.J., Management of fibromyalgia, Ann Intern Med, 131, pp. 850-858, (1999)

[24]

Wolfe F., Smythe H.A., Yunus M.B., Et al., The American College of Rheumatology 1990 criteria for the classification of fibromyalgia, Arthritis Rheum, 33, pp. 160-172, (1990)

[25]

Bendtsen L., Norregaard J., Jensen R., Olesen J., Evidence of qualitatively altered nociception in patients with fibromyalgia, Arthritis Rheum, 40, pp. 98-102, (1997)

[26]

Bennett R.M., Emerging concepts in the neurobiology of chronic pain. Evidence of abnormal sensory processing in fibromyalgia, Mayo Clin Proc, 74, pp. 385-398, (1999)

[27]

Clauw D.J., The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia, Med Hypotheses, 44, pp. 369-378, (1995)

[28]

Kosek E., Ekholm J., Hansson P., Sensory dysfunction in fibromyalgia patients with implications for pathogenetic mechanisms, Pain, 68, pp. 375-383, (1996)

[29]

Kramis R.C., Roberts W.J., Gillette R.G., Non-nociceptive aspects of persistent musculoskeletal pain, J Orthop Sports Phys Ther, 24, pp. 255-267, (1996)

[30]

Lorenz J., Grasedyck K., Bromm B., Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia syndrome, Electroencephalogr Clin Neurophysiol, 100, pp. 165-168, (1995)

← 1 2 3 4 5 6 7 8 →